AI Article Synopsis
- Abnormal accumulation of β-amyloid peptides leads to senile plaques in the brains of Alzheimer's disease patients, making it a key target for therapy.
- Resveratrol and its derivatives, known for various health benefits, have shown promise in inhibiting the formation of β-amyloid fibrils.
- The study found that ε-viniferin glucoside (VG), a dimer of resveratrol, not only prevents Aβ fibril formation but also reduces Aβ toxicity in neuronal cells, suggesting its potential as a treatment for Alzheimer's disease.
Article Abstract
Abnormal β-amyloid peptide accumulation and aggregation is considered to be responsible for the formation and cerebral deposition of senile plaques in the brains of patients with Alzheimer's disease (AD). Inhibition of the formation of β-amyloid (Aβ) fibrils would be an attractive therapeutic target for the treatment of AD. Resveratrol and its derivatives exhibit a broad range of pharmacological properties such as protection against cardiovascular diseases and cancers, as well as promoting antiaging effects. We reported previously that ε-viniferin glucoside (VG), a resveratrol-derived dimer, strongly inhibits Aβ (25-35) fibril formation in vitro. In this study, we investigated the effects of VG on the aggregation of the full-length peptides (Aβ (1-40) and Aβ (1-42)) and on the β-amyloid-induced toxicity in PC12 cells. VG inhibited Aβ cytotoxicity and the non-covalent complex between VG and Aβ was observed by electrospray ionization mass spectrometry.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmc.2011.04.001 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!